Article
Pharmacology & Pharmacy
Haoyue Hu, Songtao Tan, Meng Xie, Peng Guo, Qiang Yu, Juan Xiao, Kangrui Zhao, Qiong Liao, Yi Wang
Summary: In non-small cell lung cancer, concurrent genetic alterations of epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements are rare, but their clinical and pathological characteristics are not well-defined, and the optimal treatment approach remains controversial. This report presents a case of stage IV lung adenocarcinoma with both EGFR and ALK mutations, along with high PD-L1 expression. The patient initially received treatment with EGFR tyrosine kinase inhibitors (TKIs), but the disease progressed, and regression was achieved following a switch to ALK-TKI therapy and local radiotherapy. Our report also provides a comprehensive summary of the clinical and pathological features, as well as treatment strategies, for NSCLC patients with concurrent EGFR mutation and ALK rearrangement.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Oncology
Xiaotong Qiu, Yong Wang, Fen Liu, Lihong Peng, Chen Fang, Xiaoyin Qian, Xinwei Zhang, Qian Wang, Zhehao Xiao, Renfang Chen, Shangkun Yuan, Yong Li
Summary: Studies have shown that non-small cell lung cancer patients with EGFR mutations, but with concurrent PIK3CA mutations, treated with EGFR-TKIs have a shorter time to progression and lower overall survival rates.
AMERICAN JOURNAL OF CANCER RESEARCH
(2021)
Article
Oncology
Mengzhao Wang, James Chih-Hsin Yang, Paul L. Mitchell, Jian Fang, D. Ross Camidge, Weiqi Nian, Chao-Hua Chiu, Jianying Zhou, Yanqiu Zhao, Wu-Chou Su, Tsung-Ying Yang, Viola W. Zhu, Michael Millward, Yun Fan, Wen-Tsung Huang, Ying Cheng, Liyan Jiang, Daniel Brungs, Lyudmila Bazhenova, Chee Khoon Lee, Bo Gao, Yan Xu, Wei-Hsun Hsu, Li Zheng, Pasi A. Janne
Summary: This article reports the discovery and early clinical development of Sunvozertinib (DZD9008), a potential treatment option for EGFRexon20ins NSCLC.
Review
Oncology
Catherine B. Meador, Lecia Sequist, Zofia Piotrowska
Summary: EGFR ins20 mutations, occurring in approximately 10% of EGFR-activating mutations, have historically shown reduced sensitivity to early-generation EGFR TKIs. However, recent advancements in scientific understanding and clinical detection techniques have improved our ability to develop effective therapies for this subset of EGFR-mutant NSCLC.
Article
Oncology
Farastuk Bozorgmehr, Daniel Kazdal, Inn Chung, Martina Kirchner, Nikolaus Magios, Mark Kriegsmann, Michael Allgaeuer, Laura Klotz, Thomas Muley, Rami A. El Shafie, Juergen R. Fischer, Martin Faehling, Albrecht Stenzinger, Michael Thomas, Petros Christopoulos
Summary: This study compared the characteristics and outcomes of patients with de novo and secondary metastatic EGFR(+) NSCLC, finding no significant differences in many aspects, including age, gender, smoking history, histology, etc., and similar progression-free survival and overall survival under TKI treatment. The results indicate that the molecular features and prognosis of EGFR(+) tumors treated with TKI are independent of preceding nonmetastatic disease.
FRONTIERS IN ONCOLOGY
(2021)
Article
Multidisciplinary Sciences
Chie Morita, Tatsuya Yoshida, Masayuki Shirasawa, Ken Masuda, Yuji Matsumoto, Yuki Shinno, Shigehiro Yagishita, Yusuke Okuma, Yasushi Goto, Hidehito Horinouchi, Noboru Yamamoto, Noriko Motoi, Yasushi Yatabe, Yuichiro Ohe
Summary: Patients with Exon20ins mutations and major mutations had similar clinical characteristics, but Exon20ins patients had less satisfactory clinical outcomes compared to M-mut patients.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Jianxin Chen, Xilin Wu, Junhui Wang
Summary: The present study revealed that double-dose icotinib exposure may induce the emerging EGFR exon 20 T790M mutation in metastatic NSCLC patients. Patients with the emerging T790M mutation responded well to the treatment of targetable TKIs including almonertinib or osimertinib.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Yang Xia, Rui Jin, Miao Li, Fen Lan, Hao Zhu, Yinghui Yu, Da Miao, Qiyuan Wang, Yi Zhou, Giovanni Selvaggi, Songmin Ying, Jianjun Zhang, Huahao Shen, Xiuning Le, Wen Li
Summary: Met proto-oncogene exon 14 skipping (METex14) mutations are targetable driver genes in non-small-cell lung cancers. Ensartinib, a multi-kinase inhibitor, showed significant antitumor effects against METex14 mutant NSCLCs in preclinical and clinical trials, with low rates of adverse events.
Article
Multidisciplinary Sciences
Shen Zhao, Wu Zhuang, Baohui Han, Zhengbo Song, Wei Guo, Feng Luo, Lin Wu, Yi Hu, Huijuan Wang, Xiaorong Dong, Da Jiang, Mingxia Wang, Liyun Miao, Qian Wang, Junping Zhang, Zhenming Fu, Yihua Huang, Chunwei Xu, Longyu Hu, Lei Li, Rong Hu, Yang Yang, Mengke Li, Xiugao Yang, Li Zhang, Yan Huang, Wenfeng Fang
Summary: This study reports the safety and preliminary efficacy of a phase I clinical trial (JMT101) combining an anti-EGFR antibody with EGFR-TKI in patients with non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertions. The combination therapy demonstrated good tolerability and promising efficacy in patients.
NATURE COMMUNICATIONS
(2023)
Review
Oncology
Jiabao Hou, Hongle Li, Shuxiang Ma, Zhen He, Sen Yang, Lidan Hao, Hanqiong Zhou, Zhe Zhang, Jing Han, Li Wang, Qiming Wang
Summary: Platinum-based chemotherapy used to be the first choice for lung cancer, but EGFR tyrosine kinase inhibitors (TKIs) have become preferred treatment for NSCLC patients with EGFR gene mutations. However, patients with EGFR exon 20 insertion (ex20ins) mutations have poor prognosis and are insensitive to EGFR-TKIs. Recent clinical research has focused on developing therapies specifically targeting ex20ins mutations.
BIOMARKER RESEARCH
(2022)
Review
Oncology
Dan Yan, H. Shelton Earp, Deborah DeRyckere, Douglas K. Graham
Summary: MERTK and AXL are abnormally expressed in the majority of NSCLCs, providing a survival advantage for cells and correlating with metastasis, drug resistance, and disease progression. Host tumor infiltrating cells' TAM receptors also play crucial roles in the immunosuppressive tumor microenvironment. These factors make MERTK and AXL attractive targets for NSCLC treatment.
Review
Oncology
Rui Kitadai, Yusuke Okuma
Summary: The advent of EGFR-TKIs has significantly improved the prognosis of patients with advanced EGFR-mutant NSCLC, however, there is poor sensitivity to EGFR-TKIs in patients with uncommon EGFR mutations. This review discusses current EGFR-TKI therapy, treatment strategies, and EGFR-TKI sensitivity based on structure-function analysis.
Article
Oncology
Elizabeth S. Duke, Liza Stapleford, Nicole Drezner, Anup K. Amatya, Pallavi S. Mishra-Kalyani, Yuan -Li Shen, Kimberly Maxfield, Jeanne Fourie Zirkelbach, Youwei Bi, Jiang Liu, Xinyuan Zhang, Hezhen Wang, Yuching Yang, Nan Zheng, Kelie Reece, Emily Wearne, Jacqueline J. Glen, Idara Ojofeitimi, Barbara Scepura, Abhilasha Nair, Rama Kamesh Bikkavilli, Soma Ghosh, Reena Philip, Richard Pazdur, Julia A. Beaver, Harpeet Singh, Martha Donoghue
Summary: The FDA has granted accelerated approval for a new drug to treat adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. The approval was based on data from a clinical trial and the drug showed an overall response rate of 28% with a median duration of response of 17.5 months. Common adverse reactions include diarrhea, rash, nausea, stomatitis, vomiting, decreased appetite, paronychia, fatigue, dry skin, and musculoskeletal pain. This is the first oral targeted therapy approved for patients with advanced EGFR exon 20 insertion mutation-positive NSCLC.
CLINICAL CANCER RESEARCH
(2023)
Article
Immunology
Jun Lu, Runbo Zhong, Yuqing Lou, Minjuan Hu, Zhengyu Yang, Yanan Wang, Ya Chen, Benkun Zou, Wei Zhang, Huimin Wang, Baohui Han
Summary: This study discusses potential stratification factors for NSCLC immunotherapy using ICIs by integrating genomic profiling and tumor lesion-type information. The findings indicate that TP53 mutation status and the source of biopsy tissue should be considered when developing immunotherapy biomarkers for NSCLC patients.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Arsela Prelaj, Achille Bottiglieri, Gajanan Bhat, Rocky Washington, Giuseppina Calareso, Gabriella Francesca Greco, Roberto Ferrara, Marta Brambilla, Alessandro De Toma, Mario Occhipinti, Sara Manglaviti, Alberto Soro, Monica Ganzinelli, Giuseppe Lo Russo, Claudia Proto
Summary: Among next-generation tyrosine kinase inhibitors, poziotinib has shown effectiveness and good tolerance in patients with uncommon EFGR alterations, particularly those with EGFR exon 20 insertion mutations in metastatic non-small-cell lung cancer.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Xiao-Dong Jiao, Chunming Ding, Yuan-Sheng Zang, Guanzhen Yu
Article
Oncology
Bao-Dong Qin, Xiao-Dong Jiao, Yuan-Sheng Zang
Review
Oncology
Bao-Dong Qin, Xiao-Dong Jiao, Ke Liu, Ying Wu, Xi He, Jun Liu, Wen-Xing Qin, Zhan Wang, Yuan-Sheng Zang
FRONTIERS IN ONCOLOGY
(2019)
Letter
Oncology
Bao-Dong Qin, Xiao-Dong Jiao, Ke Liu, Ying Wu, Yuan-Sheng Zang
JOURNAL OF THORACIC ONCOLOGY
(2019)
Article
Biotechnology & Applied Microbiology
Ke Liu, Xiao-Dong Jiao, Jie-Lu Hao, Bao-Dong Qin, Ying Wu, Wei Chen, Jun Liu, Xi He, Yuan-Sheng Zang
ONCOTARGETS AND THERAPY
(2019)
Article
Respiratory System
Xiao-Dong Jiao, Xi He, Bao-Dong Qin, Ke Liu, Ying Wu, Jun Liu, Ting Hou, Yuan-Sheng Zang
JOURNAL OF THORACIC DISEASE
(2019)
Review
Oncology
Bao-Dong Qin, Xiao-Dong Jiao, Jun Liu, Ke Liu, Xi He, Ying Wu, Yan Ling, Xiao-Peng Duan, Wen-Xing Qin, Zhan Wang, Yuan-Sheng Zang
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2020)
Article
Biotechnology & Applied Microbiology
Jin-Ju Guo, Xiao-Dong Jiao, Ying Wu, Bao-Dong Qin, Ke Liu, Yuan-Sheng Zang
ONCOTARGETS AND THERAPY
(2020)
Article
Oncology
Xiao-Dong Jiao, Xiao-Chun Zhang, Bao-Dong Qin, Dong Liu, Liang Liu, Jian-Jiao Ni, Zhou-Yu Ning, Ling-Xiang Chen, Liang-Jun Zhu, Song-Bing Qin, Jian-Ya Zhou, Shen-Peng Ying, Xue-Qin Chen, Ai-Jun Li, Ting Hou, Han Han-Zhang, Junyi Ye, Jingjing Zheng, Shannon Chuai, Yuan-Sheng Zang
ANNALS OF TRANSLATIONAL MEDICINE
(2020)
Article
Oncology
Xiao-Dong Jiao, Ke Liu, Mingyan Xu, Guanzhen Yu, Danni Liu, Tanxiao Huang, Bao-Dong Qin, Ming Liu, Ying Wu, Yan Ling, Jun Liu, Xi He, Liangzhe Wang, Yingmei Li, Shifu Chen, Yuan-Sheng Zang
Summary: This article reports a successful treatment of advanced metastatic low-grade sarcoma patient with an accurate molecular pathological diagnosis obtained through NGS, followed by oral crizotinib therapy for 40 months. Whole genome sequencing analysis revealed a possible whole genome duplication event in the tumor.
Article
Oncology
Xiao-Dong Jiao, Ke Liu, Ying Wu, Xin-Cheng Zhou, Bao-Dong Qin, Yan Ling, Jun Liu, Xi He, Haiwei Du, Jianxing Xiang, Yuan-Sheng Zang
Summary: The combination of trastuzumab with chemotherapy is considered the standard therapy for HER2-positive advanced gastric cancer, but most patients eventually develop trastuzumab resistance. This study is the first to implicate HER2 c.1899-1G>A as the acquired resistance mechanism to trastuzumab in HER2-positive gastric adenocarcinoma. Insights into potential molecular mechanisms of trastuzumab resistance are crucial for developing effective therapeutic strategies for refractory HER2-positive gastric cancer patients.
Article
Oncology
Xiao-Dong Jiao, Li-Ren Ding, Chuan-Tao Zhang, Bao-Dong Qin, Ke Liu, Lian-Ping Jiang, Xi Wang, Li-Ting Lv, Hao Ding, Dao-Ming Li, Hui Yang, Xue-Qin Chen, Wen-Yu Zhu, Ying Wu, Yan Ling, Xi He, Jun Liu, Lin Shao, Hao-Zhe Wang, Yan Chen, Jing-Jing Zheng, Naoki Inui, Yuan-Sheng Zang
Summary: This study prospectively analyzed the concordance between blood and tissue genomic profiles in patients with advanced lung adenocarcinoma, finding that serum tumor markers levels higher than the normal upper limit can predict concordance, providing a new clinical predictor for treatment choices in patients with lung adenocarcinoma.
TRANSLATIONAL LUNG CANCER RESEARCH
(2021)
Article
Oncology
Shiwei Guo, Hao Qin, Ke Liu, Huan Wang, Sijia Bai, Shiyi Liu, Zhuo Shao, Yanan Zhang, Bin Song, Xiaoya Xu, Jing Shen, Peng Zeng, Xiaohan Shi, Hao Chen, Suizhi Gao, Jiajia Xu, Yaqi Pan, Lei Xiong, Fugen Li, Dadong Zhang, Xiaodong Jiao, Gang Jin
Summary: This study showed that blood small EV miR-95-3p/miR-26b-5p combined with CA19-9 could differentiate between PDAC and CP, while miR-335-5p/miR-340-5p were associated with PDAC metastasis and poor prognosis.
CLINICAL AND TRANSLATIONAL MEDICINE
(2021)
Article
Oncology
Xi He, Xiao-Dong Jiao, Ke Liu, Bao-Dong Qin, Ying Wu, Yan Ling, Jun Liu, A-Qiao Xu, Kun Song, Yuan-Sheng Zang
JCO PRECISION ONCOLOGY
(2021)
Article
Oncology
Bao-Dong Qin, Xiao-Dong Jiao, Xin-Cheng Zhou, Bin Shi, Jian Wang, Ke Liu, Ying Wu, Yan Ling, Yuan-Sheng Zang
Summary: The study evaluated the impact of concomitant PPI use on the efficacy of ICIs in advanced cancer patients, finding that PPI use was associated with reduced PFS and OS.